151-165 of 917
Fluid restriction may not be needed in chronic HF
ACC Action CenterFluid restriction may not be needed in chronic HF
Roland Kimmenade, MD, PhD
Secondary prevention strategy led by nurses reduces MACE risk after an ACS
ACC Action CenterSecondary prevention strategy led by nurses reduces MACE risk after an ACS
Giulia Magnani, MD, PhD
Secondary prevention post-ACS: a nurse-led intervention strategy
ACC Action CenterSecondary prevention post-ACS: a nurse-led intervention strategy
Laura Davidson, MD
Intensive medical therapy does not reduce MACE risk in women with INOCA
ACC Action CenterIntensive medical therapy does not reduce MACE risk in women with INOCA
Eileen Handberg, PhD
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
ACC Action CenterSemaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
Marc Bonaca, MD
Ticagrelor antidote restores platelet function in phase 3 study
ACC Action CenterTicagrelor antidote restores platelet function in phase 3 study
Deepak Bhatt, MD
- advertisement
Complexities in ATTR-CM Care: Key Considerations for Accurate Diagnosis
Heart MattersComplexities in ATTR-CM Care: Key Considerations for Accurate Diagnosis
Gautam Nayak, MD
Advances in Care for ATTR-CM: Current and Emerging Strategies
Heart MattersAdvances in Care for ATTR-CM: Current and Emerging Strategies
Gautam Nayak, MD
Treating ATTR-CM: Current Strategies and Emerging Options
Heart MattersTreating ATTR-CM: Current Strategies and Emerging Options
Frederick Ruberg, MD
Addressing Unmet Needs in ATTR-CM Care: Key Considerations for Optimal Management
Heart MattersAddressing Unmet Needs in ATTR-CM Care: Key Considerations for Optimal Management
Michelle Kittleson, MD, PhD
Overcoming Challenges in ATTR-CM Care: Best Practices for Accurate Diagnosis
Heart MattersOvercoming Challenges in ATTR-CM Care: Best Practices for Accurate Diagnosis
Michelle Kittleson, MD, PhD
Understanding the Pathophysiology Behind ATTR-CM
Heart MattersUnderstanding the Pathophysiology Behind ATTR-CM
Frederick Ruberg, MD
- advertisement
Cost-Effectiveness of Universal vs. Selective Screening for ATTR-CM in HFpEF Patients
Heart MattersCost-Effectiveness of Universal vs. Selective Screening for ATTR-CM in HFpEF Patients
Kibum Kim, PhD
ATTR-CM Screening: How Economic Factors Can Impact Care
Heart MattersATTR-CM Screening: How Economic Factors Can Impact Care
Kibum Kim, PhD
Patient Case: ATTRwt-CM Discovered Decades After Heart Transplant
Heart MattersPatient Case: ATTRwt-CM Discovered Decades After Heart Transplant
Lily Stern, MD
